Filing summary
Entity and period mismatch: The supplied filing is Rosewind Corporation’s Form 10-Q, not an AYTU Biopharma filing. It covers the quarter and six months ended February 28, 2015; it does not correspond to the metadata period “2014 Q2.” Financial amounts below are as reported in the filing.
Business context and reporting period
Rosewind described its business as offshore sailing instruction using its sailing vessel. It reported no revenue for the three- or six-month periods presented. Management said the company had conducted training voyages and earned $6,250 in total net revenue across prior voyages. The financial statements are unaudited.
Financial results and liquidity
- Revenue: $0 for the three and six months ended February 28, 2015, and for both comparable 2014 periods.
- Net loss: $9,875 for the quarter, versus $22,196 a year earlier; $25,629 for six months, versus $38,703. Six-month basic and diluted loss per share was reported as $0.00, versus $0.01 in 2014.
- Expenses: Six-month operating expenses were $24,692, down from $35,566. Six-month interest expense was $937, down from $3,137. With no revenue, operating margins are not meaningful.
- Cash flow: Six-month cash used in operations was $22,723, compared with $15,194 in 2014. Financing provided $20,508, including $15,000 from common stock and $5,508 in related-party loans. Cash declined by $2,215 to $100.
- Balance sheet: At February 28, 2015, assets were $7,985 and current liabilities were $60,903, including $36,493 in related-party loans and $18,544 in accrued related-party interest. Working capital deficit was $53,774; shareholders’ deficit was $52,918.
- Related-party financing: The officer’s secured note bears 6% interest, is payable on demand, and is secured by the sailing vessel.
Changes versus the prior comparable period
Six-month net loss improved by $13,074, or 34%, primarily as reported due to lower boat repair and maintenance and management expenses, lower consulting expenses, and reduced interest expense. Professional fees increased 47%. Despite the lower loss, operating cash use increased year over year, and cash on hand was only $100 at period-end.
Outlook, risks, and unusual items
- Management stated that substantial doubt exists about the company’s ability to continue as a going concern. It planned to seek additional equity funding, with no assurance of success; the filing says current cash is insufficient to sustain the business.
- Management said student revenue remained unproven and described continued funding needs for operations, repairs, travel, supplies, and marketing. The filing provided no quantified revenue or earnings guidance.
- Risks include limited operating history and market acceptance, substantial ongoing losses, dependence on a sole officer, possible dilution, regulatory and tax uncertainty, and limited insurance for the vessel and operations.
- Management was evaluating a possible change of business through a transaction with a company in an unrelated business; no definitive agreement had been signed. The prospective business was described as unproven, with little or no current cash revenue and projected significant negative cash flow.
- Subsequent event: On March 3, 2015, Rosewind issued 13.6 million restricted shares to two accredited investors for $25,000 in connection with a potential reverse merger. The filing reported 19,435,402 common shares outstanding as of April 15, 2015.
- The filing contains inconsistent accumulated-deficit amounts: the balance sheet reports $656,056, the equity statement reports $655,556 at February 28, 2015, and the risk-factor text gives another amount. The filing text does not provide a clear reconciled value.
Important facts for investors to verify
- Confirm that this Rosewind filing is the intended document; it does not identify AYTU Biopharma as the registrant.
- Reconcile the accumulated-deficit figures and verify the reported working-capital deficit and related-party loan and accrued-interest balances.
- Verify the terms, ownership effects, and subsequent status of the 13.6 million-share issuance and potential reverse merger.
- Assess near-term funding needs and the going-concern warning, given $100 in period-end cash and continued operating cash outflows.
- Verify the status of sailing-school revenue, required regulatory permissions, and adequate insurance coverage.